Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Fei, Xiang, Rong, Deng, Xiaoqian, Wang, Lili, Yu, Zhengsen, Tian, Shijun, Liang, Ruiying, Li, Yanbai, Ying, Tianlei, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506210/
https://www.ncbi.nlm.nih.gov/pubmed/32963228
http://dx.doi.org/10.1038/s41392-020-00318-0
_version_ 1783584981093711872
author Yu, Fei
Xiang, Rong
Deng, Xiaoqian
Wang, Lili
Yu, Zhengsen
Tian, Shijun
Liang, Ruiying
Li, Yanbai
Ying, Tianlei
Jiang, Shibo
author_facet Yu, Fei
Xiang, Rong
Deng, Xiaoqian
Wang, Lili
Yu, Zhengsen
Tian, Shijun
Liang, Ruiying
Li, Yanbai
Ying, Tianlei
Jiang, Shibo
author_sort Yu, Fei
collection PubMed
description The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.
format Online
Article
Text
id pubmed-7506210
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75062102020-09-23 Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2 Yu, Fei Xiang, Rong Deng, Xiaoqian Wang, Lili Yu, Zhengsen Tian, Shijun Liang, Ruiying Li, Yanbai Ying, Tianlei Jiang, Shibo Signal Transduct Target Ther Review Article The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development. Nature Publishing Group UK 2020-09-22 /pmc/articles/PMC7506210/ /pubmed/32963228 http://dx.doi.org/10.1038/s41392-020-00318-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Yu, Fei
Xiang, Rong
Deng, Xiaoqian
Wang, Lili
Yu, Zhengsen
Tian, Shijun
Liang, Ruiying
Li, Yanbai
Ying, Tianlei
Jiang, Shibo
Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
title Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
title_full Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
title_fullStr Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
title_full_unstemmed Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
title_short Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
title_sort receptor-binding domain-specific human neutralizing monoclonal antibodies against sars-cov and sars-cov-2
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506210/
https://www.ncbi.nlm.nih.gov/pubmed/32963228
http://dx.doi.org/10.1038/s41392-020-00318-0
work_keys_str_mv AT yufei receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT xiangrong receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT dengxiaoqian receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT wanglili receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT yuzhengsen receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT tianshijun receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT liangruiying receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT liyanbai receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT yingtianlei receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2
AT jiangshibo receptorbindingdomainspecifichumanneutralizingmonoclonalantibodiesagainstsarscovandsarscov2

Ejemplares similares